Hubei Cancer Hospital Conducts Clinical Trial for Reversing Resistance to Immunotherapy in Lung Cancer

Strategic Insights -

Researchers at Hubei Cancer Hospital have initiated a clinical trial aimed at reversing resistance to first-line PD(L)-1 monoclonal antibody combination therapy in stage IV non-small cell lung cancer patients with negative driver genes. The trial, registered with the Chinese Clinical Trial Registry (ChiCTR), seeks to explore the efficacy of combining original regimen immunotherapy with chemotherapy, low-dose radiotherapy, and stereotactic radiotherapy in patients who have developed resistance to first-line immunotherapy. The study's primary objective is to assess the progression-free survival (PFS) of this regimen in patients with driver-negative stage IV non-small-cell lung cancer.

Key Takeaways:

  • The clinical trial, identified by the registration number ChiCTR2500107185, aims to reverse resistance to first-line immunotherapy in stage IV non-small cell lung cancer patients with negative driver genes.
  • The study will evaluate the efficacy of combining original regimen immunotherapy with chemotherapy, low-dose radiotherapy, and stereotactic radiotherapy in patients resistant to first-line immunotherapy.
  • The primary objective of the trial is to assess the progression-free survival (PFS) of this regimen in patients with driver-negative stage IV non-small-cell lung cancer.
  • Secondary objectives include evaluating the efficacy of the regimen, treatment-related toxicity, and exploring the correlation between peripheral lymphocyte subpopulation analysis, hemocyte factors, and the efficacy and immune activation and immunosuppression status.
  • The trial will utilize the Evaluation Criteria for Solid Tumors (RECISTv1.1) to assess the efficacy of the treatment.
  • The study plans to enroll patients with driver-negative stage IV non-small-cell lung cancer who have developed resistance to first-line immunotherapy.

Statistics:

  • The study will be conducted at the Hubei Cancer Hospital.
  • The trial is registered with the Chinese Clinical Trial Registry (ChiCTR) under registration number ChiCTR2500107185.
  • The study type is Interventional.
  • The objectives of the study aim to assess the progression-free survival (PFS), efficacy, and treatment-related toxicity of the regimen.
  • The trial plans to evaluate the efficacy of the treatment in patients with driver-negative stage IV non-small-cell lung cancer.

Sources:

  • Chinese Clinical Trial Registry (ChiCTR) under registration number ChiCTR2500107185.